GlassScriptPhysician profile
Theodore K Lee
NPI 1154716967
$4,157.75
in general payments reported to CMS, 2019-2025
18 companies · $969 in 2025
The $969 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.28 · 2021: $237 · 2022: $689 · 2023: $1,244 · 2024: $999 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141 · Education: $71.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.46 |
| Education | $71.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,547.52 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $628.33 | 2021-2025 | Dupixent |
| Genzyme Corporation | $551.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $301.79 | 2021-2024 | Nucala |
| Amgen INC. | $248.68 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $204.72 | 2023-2025 | |
| Incyte Corporation | $170.60 | 2022-2025 | Opzelura |
| Pharming Healthcare, INC. | $100.21 | 2023-2024 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $74.43 | 2022-2025 | Cuvitru, Hyqvia |
| Grifols USA, LLC | $68.43 | 2021-2022 | |
| Genentech USA, INC. | $59.91 | 2022-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $50.71 | 2025 | Neffy |
| Blueprint Medicines Corporation | $47.45 | 2024 | Ayvakit |
| Pfizer INC. | $28.99 | 2023 | |
| Phadia US INC. | $23.97 | 2024 | Immunocap |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $19.28 | 2020 | |
| Aimmune Therapeutics, INC. | $16.88 | 2021 | |
| Galderma Laboratories, L.P. | $14.32 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.